Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfg393 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma.
Cells
May 2024
Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Glioblastoma (GBM) is the most common yet uniformly fatal adult brain cancer. Intra-tumoral molecular and cellular heterogeneities are major contributory factors to therapeutic refractoriness and futility in GBM. Molecular heterogeneity is represented through molecular subtype clusters whereby the proneural (PN) subtype is associated with significantly increased long-term survival compared to the highly resistant mesenchymal (MES) subtype.
View Article and Find Full Text PDFPOLR2J expression promotes glioblastoma malignancy by regulating oxidative stress and the STAT3 signaling pathway.
Am J Cancer Res
May 2024
Taizhou Boai Hospital, Affiliated Luqiao Hospital, School of Medicine, Hangzhou City University Hangzhou 310015, Zhejiang, China.
Glioblastoma is the most common cancer in the brain, resistant to conventional therapy and prone to recurrence. Therefore, it is crucial to explore novel therapeutics strategies for the treatment and prognosis of GBM. In this study, through analyzing online datasets, we elucidated the expression and prognostic value of POLR2J and its co-expressed genes in GBM patients.
View Article and Find Full Text PDFStimulation of tumoricidal immunity via bacteriotherapy inhibits glioblastoma relapse.
Nat Commun
May 2024
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.
Article Synopsis
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor that poses significant treatment challenges due to its invasive nature and compromised immune response, leading to treatment failures and tumor recurrence.
- Researchers developed a novel bacterium-hydrogel superstructure that targets and destroys residual GBM cells, enhancing immune responses to prevent postoperative relapse.
- The system utilizes engineered Salmonella vehicles combined with nanocapsules to stimulate an immune response and promote the recruitment of immune cells, showing promise for treating patients with GBM at high risk of recurrence.
Columbianadin suppresses glioblastoma progression by inhibiting the PI3K-Akt signaling pathway.
Biochem Pharmacol
May 2024
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, Zhejiang, China. Electronic address:
Glioblastoma (GBM) is the most common malignant glioma among brain tumors with low survival rate and high recurrence rate. Columbianadin (CBN) has pharmacological properties such as anti-inflammatory, analgesic, thrombogenesis-inhibiting and anti-tumor effects. However, it remains unknown that the effect of CBN on GBM cells and its underlying molecular mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!